Skip to content

genetic test evaluation in carcinoma of pancreas

â??An integrated network analysis to identify genomic alteration profiles of human pancreatic cancer.â??

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/08/015556
Enrollment
25
Registered
2018-08-31
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C259- Malignant neoplasm of pancreas, unspecified Health Condition 2: C259- Malignant neoplasm of pancreas, unspecified

Interventions

None listed

Sponsors

Tata Memorial Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients surgically resected for peri-ampullary tumorsof pancreatic origin, without any neoadjuvant treatment.

Exclusion criteria

Exclusion criteria: The patients who received prior treatment before surgery will be excluded.

Design outcomes

Primary

MeasureTime frame
Exploratory study for identification of genes mutated in Pancreatic periampullary cancer by whole exome sequencing approach to map somatic mutations, deletions and point mutations and selecting genes which are significantly alteredTimepoint: 36 months

Secondary

MeasureTime frame
Functional analysis and Prediction of new therapeutic targets in pancreatic cancer to facilitate personalized approach for cancer therapy.Timepoint: 36 months

Countries

India

Contacts

Public ContactDr Shailesh Vinayak Shrikhande

Tata Memorial Hospital

shailushrikhande@hotmail.com9820224761

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026